Allen, M. H. (2000). Managing the agitated psychotic patient: A reappraisal of the evidence. Journal of Clinical Psychiatry, 61(Suppl. 14), 11-20.
2.
Baldessarini, R. J., Cohen, B. M., & Teicher, M. H. (1988). Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry, 45, 79-91.
3.
Barnes, T. R. (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672-676.
4.
Beers, M. H., & Berkow, R. (Eds.). (1999). Psychiatric emergencies. Merck manual of diagnosis and therapy. Retrieved March 28, 2002, from http://www.merck.com/pubs/mmanual/section15/chapter194/194a.htm
5.
Breier, A., Meehan, K., Birkett, M., David, S., Ferchland, I., Sutton, V., et al. (2002). A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry, 59, 441-448.
6.
Brook, S., Lucey, J. V., & Gunn, K. P. (2000). IM ziprasidone compared with IM haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. Journal of Clinical Psychiatry, 61, 933-941.
7.
Buchanan, W., & Carpenter, W. T. (2000). Schizophrenia: Introduction and interview. In B. J. Sadock & V. A. Sadock (Eds.), Kaplan and Sadock’s comprehensive textbook of psychiatry (pp. 1204). Philadelphia: Lippincott Williams & Wilkins.
8.
Casey, D. E. (1995). Motor and mental aspects of extrapyramidal syndromes. International Clinical Psychopharmacology, 10(Suppl. 3), 105-114.
9.
Clinton, J. E., Sterner, S., Stelmachers, Z., & Ruiz, E. (1987). Haloperidol for sedation of disruptive emergency patients. Annals of Emergency Medicine, 16, 319-322.
10.
Cure, S., & Carpenter, S. (2001). Droperidol for acute psychosis. Cochrane Database System Review, 2, CD002830.
11.
Currier, G. W., & Allen, M. H. (1999, October-November). Psychiatric emergency service structure and function. Paper presented at the Institute for Psychiatric Services, New Orleans, LA.
12.
Currier, G. W., & Simpson, G. M. (2001). Risperidone liquid concentrate and oral lorazepam versus IM haloperidol and IM lorazepam for treatment of psychotic agitation. Journal of Clinical Psychiatry, 62, 153-157.
13.
Currier, G. W., & Trenton, A. (2002). Pharmacological treatment of psychotic agitation. CNS Drugs, 16, 219-228.
14.
Daniel, D. G., Potkin, S. G., Reeves, K. R., Swift, R. H., & Harrigan, E. P. (2001). Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial. Psychopharmacology, 155, 128-134.
15.
Donlon, P. T., Hopkin, J., & Tupin, J. P. (1979). Overview: Efficacy and safety of the rapid neuroleptization method with injectable haloperidol. American Journal of Psychiatry, 136, 273-278.
16.
Eli Lilly. Zyprexa powder for solution for injection. Summary of product characteristics. Retrieved from http://www.lilly.co.uk/pdf/zyprexa%20IM.pdf
17.
FDA strengthens warnings for droperidol (n.d.). From http://www.fda.gov/bbs/topics/ANSWERS/2001/ANS01123.html
18.
FDA Psychopharmacological Drugs Advisory Committee (n.d.). Briefing document for Zyprexa® IM (olanzapine for injection). Retrieved from http://www.fda.gov/ohrms/dockets/ac/01/briefing/3685b1_01_lilly.pdf
19.
Geodon [package insert]. (2002). New York: Pfizer Inc.
20.
Goodnick, P. J. (2001). Ziprasidone: Profile on safety. Expert Opinion on Pharmacotherapy, 2, 1655-1662.
21.
Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: U.S. Department of Health, Education, and Welfare.
22.
Haldol [package insert]. (2001). Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.
23.
Kay, S., Opler, L., & Fiszbein, A. (1986). Positive and Negative Syndrome Scale (PANSS) manual. North Tonawanda, NY: Multi-Health Systems.
24.
Lenox, R. H., Modell, J. G., & Weiner, S. (1986). Acute treatment of manic agitation with lorazepam. Psychosomatics, 27 (Suppl. 1), 28-32.
25.
Lesem, M. D., Zajecka, J. M., Swift, R. H., Reeves, K. R., & Harrigan, E. P. (2001). Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. Journal of Clinical Psychiatry, 62, 12-18.
26.
Meehan, K. M., Wang, H., David, S. R., Nisivoccia, J. R., Jones, B., Beasley, C. M., et al. (2002). Comparison of rapidly acting intra-muscular olanzapine, lorazepam, and placebo. A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology, 26, 494-504.
27.
Meehan, K. M., Zhang, F., David, S., Tohen, M., Janicak, P., Small, J., et al. (2001). A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology, 21, 389-397.
28.
Meltzer, H. Y. (1993). New drugs for the treatment of schizophrenia. The Psychiatry Clinics of North America, 16, 365-385.
29.
Meltzer, H. Y., & McGurk, S. R. (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin, 25, 233-255.
30.
Pfizer, Inc. (n.d.). [Cardiac data related to ziprasidone on file]. New York: Author.
31.
Reeves, K. R., Swift, R. H., & Harrigan, E. P. (1998). A comparison of rapid-acting intramuscular (IM) ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation. Presented at the 9th Congress of the Association of European Psychiatrists, Copenhagen, Denmark.
32.
Simpson, G. M., & Angus, J. (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, 212 (Suppl. 44), 11-19.
33.
Swift, R. H., Harrigan, E. P., Cappelleri, J. C., Kramer, D., & Chandler, L. P. (2002). Validation of the Behavioural Activity Rating Scale (BARS): A novel measure of activity in agitated patients. Journal of Psychiatric Research, 36, 87-95.
34.
U.S. Department of Health and Human Services. (2001). Psychopharmacological Drugs Advisory Committee Meeting on NDA 21-253: Zyprexa. Retrieved from http://www.fda/gov/ohrms/dockets/ac/01/slides/3685s1.htm
35.
Weiden, P. J., Mann, J. J., Haas, G., Mattson, M., & Frances, A. (1987). Clinical nonrecognition of neuroleptic-induced movement disorders: A cautionary study. American Journal of Psychiatry, 144, 1148-1153.
36.
Woerner, M. G., Mannuza, S., & Kane, J. M. (1988). Anchoring the BPRS: An aid to improved reliability. Psychopharmacology Bulletin, 24, 112-117.
37.
Wright, P., Birkett, M., David, S. R., Meehan, K., Ferchland, I., Alaka, K. J., et al. (2001). Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. American Journal of Psychiatry, 158, 1149-1151.
38.
Young, D.Black-box warning for droperidol surprises pharmacists. (2002). American Journal of Health-System Pharmacy, 59, 494, 497, 502-504.
39.
Zavodnick, S. (1978). A pharmacological and theoretical comparison of high and low potency neuroleptics. Journal of Clinical Psychiatry, 39, 332-336.
